Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
| Autor: | A. Wong, J. Tujakowski, Chris Twelves, P. Garcia-Alfonso, W. I. Burns, Jim Cassidy, N. Marschner, Duncan I. Jodrell, Joseph McKendrick, Howard A. Burris, S. Begbie, G. Van Hazel, J. Zaluski, P. Koralewski, Werner Scheithauer, E. L. Levine, Jean A. Maroun, Markus Borner |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Adult
Diarrhea Male Antimetabolites Antineoplastic medicine.medical_specialty Neutropenia Nausea Colorectal cancer medicine.medical_treatment Leucovorin Administration Oral 610 Medicine & health Deoxycytidine Gastroenterology Capecitabine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Adjuvant therapy Humans Neoplasm Metastasis Aged Aged 80 and over Chemotherapy business.industry Age Factors Peripheral Nervous System Diseases Hematology Middle Aged medicine.disease Surgery Oncology Fluorouracil Colonic Neoplasms Female Safety medicine.symptom business Febrile neutropenia medicine.drug |
| Zdroj: | Scheithauer, W.; Mckendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C. (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of oncology, 14(12), pp. 1735-1743. Oxford University Press 10.1093/annonc/mdg500 |
| Popis: | Background: Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer. Patients and methods: Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m2 twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m2 with i.v. leucovorin 20 mg/m2 on days 1-5, repeated every 28 days (n = 974). Results: Patients receiving capecitabine experienced significantly (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|